Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

INTERVIEW: GtreeBNT Looks To Novelty, Deals To Become Dry Eye Player

Executive Summary

GtreeBNT is looking to challenge one of the biggest ophthalmology sectors through a novel dry eye syndrome drug with multiple mechanisms of action that the South Korean venture believes can help it carve a significant global niche, helped by international licensing deals.

You may also be interested in...



GtreeBNT Aims To Validate Business Model Via Licensing Deals

2017 may be a milestone year for GtreeBNT as it progresses its late clinical stage pipeline in the US for various high-need indications including glioblastoma, the South Korean bioventure’s CEO assuring investors that he expects to see “good results” in the near future as it seeks licensing deals for its assets.

Korea Regulatory Streamlining Plans Eye Innovation, Commercialization Support

South Korea's drug ministry, together with consumer and business groups, announces a raft of major regulatory innovation tasks it aims to achieve over the next few years, a major goal being to speed up patient access to innovation.

Asia Deal Watch: Hansoh, TiumBio Join Forces On Endometriosis Drug In Greater China

Plus deals involving Shionogi/ Grünenthal, CR Biopharma/ImmVira, Elevation Oncology/CSPC, Everest Medicines/TTY Biopharm and Dr. Reddy’s/Slayback

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC097543

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel